- This event has passed.
RARE Partnering & Investor Forum
September 14, 2017
THE FIRST-EVER RARE DISEASE PARTNERING EVENT WHERE SCIENCE INNOVATORS AND INVESTORS CONVERGE
Early Bird Registration Pricing Ends July 31st
EBD Group’s 1:1 Partnering Platform * Panel Discussions with Industry Experts * Company Presentations * ‘Shark Tank’-Style Pitch Competition Featuring Promising Early Stage Companies
Participating Partners and Investors (to date):
John Crowley, Chairman and CEO, Amicus Therapeutics
Brad Margus, Founder & CEO, Cerevance
Bharatt Chowrira, President & Chief of Business & Strategy, PureTech Health
Camille Samuels, Managing Partner, Venrock
Neil Kumar, CEO, BridgeBio
Alison Silva, CEO & President
Critical Outcome Technologies Inc., The Orphan Group
Michael Pistone, Strategic Marketing & Business Development, Cincinnati Children’s Hospital
Matthew Howes, EVP, Strategy & Growth, Palio
Jeremy Springhorn, Flagship Pioneering
Ashish Sagrolikare, Office of Commercial Transformation, GSK
Art Pappas, Managing Partner, Pappas Capital
Vern Norviel, Partner, Wilson Sonsini Goodrich & Rosati
Kush Parmar, MD, Ph.D., Managing Partner, 5AM Ventures
Michael Broxson, VP, Manager Business Development, Takeda Pharmaceuticals
Innovators and Investors will converge at RARE Partnering, an event not to be missed. #2017GGForum.
For more information on partnering, email Nicoleb@globalgenes.org.
Thank you to our Sponsors:
Cincinnati Children’s, EBD Group, Horizon Pharma, Retrophin, The Scientist, Ultragenyx Pharmaceutical, inVentiv Health
Alliance for Regenerative Medicine, Cerevance, CLSA, Critical Outcome Technologies Inc.